Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

Key Inclusion Criteria:

• Are at least 18 years old (or old enough to legally make their own treatmentdecisions, according to local laws).

• Have advanced NSCLC or metastatic NSCLC (NSCLC that started in the lungs and thenspread to other parts of the body) with the KRAS G12C mutation.

• Have had previous treatment with 1) chemotherapy that included a drug calledcisplatin or a drug called carboplatin and 2) a type of drug called an immunecheckpoint inhibitor.

• Have recovered from their prior treatment and blood tests are within a safe range.

Key Exclusion Criteria:

• Have had previous treatment with a drug that targets KRAS G12C.

• Have cancer that can potentially be removed with surgery.

• Patients with brain lesions are not eligible if 1) any untreated brain lesions are > 2.0 cm in size 2) any brainstem lesions are present 3) ongoing steroid dosing >10 mgdaily prednisone (or equivalent) and 4) poorly controlled (> 1/week) generalized orcomplex partial seizures or neurologic progression/instability due to brain lesions.

• Have certain medical conditions or need to take certain medications that, in theopinion of a trial doctor, could make it unsafe for them to participate or difficultto complete the trial assessments, or are pregnant.